A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.


Updates from The Motley Fool

Latest updates on Geron from Fool.com.


Stock Performance

GERN vs. S&P 500 | 2 Year Performance
View Interactive GERN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Geron.
Current Price: $2.69
Prev Close: $2.69
Open: $2.68
Bid: $2.60
Ask: $2.87
Day's Range: $2.64 - $2.72
52wk Range: $2.30 - $5.30
Volume: 1,284,154
Avg Vol 1,131,735
Market Cap: $425.62M
P/E (ttm): 269.00
EPS (ttm): $0.01
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Geron.
CAPS Rating 3 out of 5
 
647 Outperform
60 Underperform
CAPS All Stars
 
82 Outperform
16 Underperform

How do you think Geron will perform against the market?



You pick for Geron is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John A. Scarlett, CEO

100% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Geron.

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers